Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | FLT1 | P17948 | 1/20 | 0.46 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 5/20 | 0.45 |
| ▸ | CA1 | P00915 | 5/20 | 0.45 |
| ▸ | CA2 | P00918 | 5/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2430255 | 0.95 | KDM4E (0.50) | MAPTALDH1A1GAAKDM4EHSD17B10 | |
| SCHEMBL3187202 | 0.93 | KDM4E (0.48) | MAPTALDH1A1GAAKDM4EHSD17B10 | |
| SCHEMBL3198146 | 0.91 | KDM4E (0.47) | MAPTALDH1A1GAAKDM4EHSD17B10 | |
| SCHEMBL232535 | 0.90 | MAPT (0.48) | MAPTALDH1A1GAAKDM4EHSD17B10 | |
| SCHEMBL4101519 | 0.86 | KDM4E (0.44) | MAPTALDH1A1GAAKDM4EHSD17B10 | |
| SCHEMBL30182718 | 0.86 | KDM4E (0.44) | MAPTALDH1A1GAAKDM4EHSD17B10 | |
| SCHEMBL15957613 | 0.86 | MAPT (0.44) | MAPTALDH1A1GAAKDM4EHSD17B10 | |
| SCHEMBL15544006 | 0.85 | KDM4E (0.43) | MAPTALDH1A1GAAKDM4EHSD17B10 | |
| SCHEMBL15957647 | 0.85 | SMN1; SMN2 (0.43) | MAPTALDH1A1GAAKDM4EHSD17B10 | |
| SCHEMBL30833248 | 0.85 | KDM4E (0.43) | MAPTALDH1A1GAAKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295197-A1 | STAT5 and STAT6 Degraders and Uses Thereof | REGENTS OF THE UNIV OF MICHICAN (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295197-A1 | STAT5 and STAT6 Degraders and Uses Thereof | REGENTS OF THE UNIV OF MICHICAN (US) | 2023-09-21 | — | — | US | disclosed |
| WO-2023103850-A1 | SMALL MOLECULE STING AGONIST, PREPARATION METHOD THEREFOR, AND APPLICATION | 中国科学院上海药物研究所 | 2023-06-15 | — | — | WO | disclosed |
| US-11034690-B2 | Heterocyclic modulators of lipid synthesis | Saginiet Biosciences Inc. (US) | 2021-06-15 | — | — | US | disclosed |
| EP-3190108-B1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC (US) | 2021-05-19 | — | — | EP | disclosed |
| US-20200207716-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2020-07-02 | — | — | US | disclosed |
| US-20190308969-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC. | 2019-10-10 | — | — | US | disclosed |
| EP-2870150-B1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3 V BIOSCIENCES INC (US) | 2019-06-19 | — | — | EP | disclosed |
| US-10233192-B2 | Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents | WILLIAM MARSH RICE UNIVERSITY (US) | 2019-03-19 | — | — | US | disclosed |
| US-20180222892-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V BIOSCIENCES, INC. | 2018-08-09 | — | — | US | disclosed |
| CN-103657631-A | Catalyst and method for producing carboxylic acid and/or carboxylic anhydride in the presence of the catalyst | MITSUBISHI GAS CHEMICAL CO | 2014-03-26 | — | — | CN | disclosed |
| CN-101632925-B | Catalyst and process for producing carboxylic acid and/or carboxylic acid anhydride using the same | MITSUBISHI GAS CHEMICAL CO | 2014-02-26 | — | — | CN | disclosed |
| US-20130149281-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2013-06-13 | — | — | US | disclosed |
| US-8445527-B2 | Organic compounds and their uses | NOVARTIS AG (CH) | 2013-05-21 | — | — | US | disclosed |
| US-8357625-B2 | Catalyst and method for producing carboxylic acid and/or carboxylic anhydride in the presence of the catalyst | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2013-01-22 | — | — | US | disclosed |
| US-20100036138-A1 | CATALYST AND METHOD FOR PRODUCING CARBOXYLIC ACID AND/OR CARBOXYLIC ANHYDRIDE IN THE PRESENCE OF THE CATALYST | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2010-02-11 | — | — | US | disclosed |
| CN-101632925-A | Catalyst and process for producing carboxylic acid and/or carboxylic acid anhydride using the same | MITSUBISHI GAS CHEMICAL CO | 2010-01-27 | — | — | CN | disclosed |
| EP-2135671-A2 | Catalyst and method for producing carboxylic acid and/or carboxylic anhydride in the presence of the catalyst | Mitsubishi Gas Chemical Company, Inc. (JP) | 2009-12-23 | — | — | EP | disclosed |
| US-5171880-A | Sulfur or oxidized sulfur in a base | ALLIED-SIGNAL INC. (US) | 1992-12-15 | — | — | US | disclosed |
| US-5171891-A | Using sulfur containing oxy acids and their salts | ALLIED-SIGNAL INC. (US) | 1992-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10233192-B2 | Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents | UNC119, UNC93B1, RIOX2 | MAPT 3083/4885ALDH1A1 1977/4885GAA 342/4885 |
| US-20180222892-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, FADS2 | MAPT 4059/4885ALDH1A1 879/4885GAA 410/4885 |
| US-20130149281-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, HAVCR2, CPT1A | MAPT 1378/4885ALDH1A1 153/4885GAA 56/4885 |
| US-20230295197-A1 | STAT5 and STAT6 Degraders and Uses Thereof | STAT6, STAT5B, STAT5A | MAPT 3689/4885ALDH1A1 2337/4885GAA 1083/4885 |
| US-11034690-B2 | Heterocyclic modulators of lipid synthesis | FASN, FADS1, SCD | MAPT 4329/4885ALDH1A1 724/4885GAA 1343/4885 |
| US-20190308969-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, SCD | MAPT 4193/4885ALDH1A1 687/4885GAA 1431/4885 |
| US-20200207716-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | MTOR, RICTOR, RPTOR | MAPT 1388/4885ALDH1A1 3942/4885GAA 1949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.